Clinical Trial Update: Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) [Phase 2]

View source ↗

Summary

This document describes an ongoing Phase 2 clinical trial evaluating chidamide in combination with the DICE regimen for relapsed or refractory B-cell non-Hodgki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Chidamide (chidamide)
• DEXAMETHASONE (Dexamethasone)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)

Snippet

Sponsor: Peking University | Conditions: B-cell Non-Hodgkin's Lymphoma | Phase 2 | Status: UNKNOWN